Good morning and welcome to Bausch + Lomb’s Third Quarter 2024 Earnings Call. [Operator Instructions] Please note this event ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) yesterday and set a price target of $26.00. Larry Biegelsen has given his Buy ...

Good morning and welcome to Bausch + Lomb's Third Quarter 2024 Earnings Call ... room to run as we progressively launch multifocal and toric options in new geographies. Big picture, it's clear ...

TPG and Blackstone have partnered to bid for eye care company Bausch + Lomb Corporation, according to sources cited by the Financial Times. If successful, the transaction could become one of the ...

Forget rosemary oil, batana oil is the new TikTok hair hero With scalp care being seen as an extension of skin care, interest in trending natural oils remains high. Batana, sage, and prickly pear oil ...

Diaceutics, a technology provider to the pharma and biotech industry, appointed Sandra Blake as chief people officer. Cathleen McCabe, MD has joined Bausch + Lomb as strategic medical advisor.

Bausch + Lomb has bought US and Canadian rights to a potential biosimilar competitor to Novartis’ Lucentis from Germany’s Stada, as the blockbuster approaches the end of its patent ...

Bausch Health turned down recent debt-restructuring proposals from bondholders as it explores a sale of its Bausch + Lomb vision care subsidiary that could bring in billions of dollars to pay ...

Banks and private credit firms are competing to provide at least $5 billion of debt financing to help fund a potential buyout of Bausch + Lomb, according to people with knowledge of the matter. A ...